| scholarly article | Q13442814 |
| review article | Q7318358 |
| P6179 | Dimensions Publication ID | 1034979515 |
| P356 | DOI | 10.1038/NRRHEUM.2015.88 |
| P698 | PubMed publication ID | 26122952 |
| P50 | author | Ricard Cervera i Segura | Q53547424 |
| Gerard Espinosa | Q60326205 | ||
| P2860 | cites work | Prevention of recurrent miscarriage for women with antiphospholipid antibody or lupus anticoagulant | Q24247000 |
| VTE, thrombophilia, antithrombotic therapy, and pregnancy: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines | Q24632982 | ||
| Seronegative antiphospholipid syndrome | Q24674194 | ||
| Pregnancy outcome in recurrent spontaneous abortion associated with antiphospholipid antibodies: a comparative study of intravenous immunoglobulin versus prednisone plus low-dose aspirin | Q28180882 | ||
| Thrombosis and thrombocytopenia in antiphospholipid syndrome (idiopathic and secondary to SLE): first report from the Italian Registry. Italian Registry of Antiphospholipid Antibodies (IR-APA) | Q72787619 | ||
| A multicenter, placebo-controlled pilot study of intravenous immune globulin treatment of antiphospholipid syndrome during pregnancy. The Pregnancy Loss Study Group | Q73388182 | ||
| Guidelines on the investigation and management of the antiphospholipid syndrome | Q74121684 | ||
| Thrombosis of aortic valve homograft associated with lupus anticoagulant antibodies | Q75271647 | ||
| Echocardiographic evaluation of patients with primary antiphospholipid syndrome | Q77375392 | ||
| Five-year follow-up by transesophageal echocardiographic studies in primary antiphospholipid syndrome | Q81055584 | ||
| 'Non-criteria' aPL tests: report of a task force and preconference workshop at the 13th International Congress on Antiphospholipid Antibodies, Galveston, TX, USA, April 2010 | Q83389360 | ||
| Evidence-based recommendations for the prevention and long-term management of thrombosis in antiphospholipid antibody-positive patients: report of a task force at the 13th International Congress on antiphospholipid antibodies | Q83389363 | ||
| Cardiac valve replacement in patients with antiphospholipid syndrome | Q83667355 | ||
| Nephropathy associated with antiphospholipid antibodies in patients with systemic lupus erythematosus | Q83842514 | ||
| First-trimester low-dose prednisolone in refractory antiphospholipid antibody-related pregnancy loss | Q83992557 | ||
| Effectiveness of thrombopoietin-receptor agonists in the treatment of refractory immune thrombocytopenia associated to systemic lupus erythematosus | Q85233702 | ||
| Pre-eclampsia as a manifestation of antiphospholipid syndrome: assessing the current status | Q85325186 | ||
| Identification and treatment of APS renal involvement | Q85325216 | ||
| Treatment strategies and pregnancy outcomes in antiphospholipid syndrome patients with thrombosis and triple antiphospholipid positivity. A European multicentre retrospective study | Q87375739 | ||
| Renal involvement in antiphospholipid syndrome | Q87467570 | ||
| Randomized study of subcutaneous low molecular weight heparin plus aspirin versus intravenous immunoglobulin in the treatment of recurrent fetal loss associated with antiphospholipid antibodies | Q28195353 | ||
| Management of antiphospholipid syndrome in pregnancy | Q28199914 | ||
| Primary antiphospholipid syndrome: a 5-year transesophageal echocardiographic followup study | Q28210952 | ||
| Real world experience with antiphospholipid antibody tests: how stable are results over time? | Q28218139 | ||
| International consensus statement on an update of the classification criteria for definite antiphospholipid syndrome (APS) | Q28292418 | ||
| Evaluation of cardiac abnormalities and embolic sources in primary antiphospholipid syndrome by transesophageal echocardiography | Q33334045 | ||
| Antiphospholipid antibodies and antiphospholipid syndrome in patients presenting with immune thrombocytopenic purpura: a prospective cohort study | Q33338827 | ||
| Antiphospholipid syndrome: clinical and immunologic manifestations and patterns of disease expression in a cohort of 1,000 patients | Q33341941 | ||
| Antiphospholipid-associated thrombocytopenia or autoimmune hemolytic anemia in patients with or without definite primary antiphospholipid syndrome according to the Sapporo revised classification criteria: a 6-year follow-up study | Q33390708 | ||
| Enoxaparin versus unfractionated heparin in the management of recurrent abortion secondary to antiphospholipid syndrome | Q33393738 | ||
| Task Force on Catastrophic Antiphospholipid Syndrome (APS) and Non-criteria APS Manifestations (II): thrombocytopenia and skin manifestations | Q33394044 | ||
| Clinical implications of elevated antiphospholipid antibodies in adult patients with primary immune thrombocytopenia | Q33398955 | ||
| A pilot open-label phase II trial of rituximab for non-criteria manifestations of antiphospholipid syndrome | Q33404206 | ||
| The spectrum of renal thrombotic microangiopathy in lupus nephritis | Q33405303 | ||
| Thrombotic risk in patients with immune thrombocytopenia and its association with antiphospholipid antibodies | Q33406643 | ||
| Morbidity and mortality in the antiphospholipid syndrome during a 10-year period: a multicentre prospective study of 1000 patients | Q33412915 | ||
| Antiphospholipid syndrome in renal transplantation | Q33413394 | ||
| Efficacy and safety of rituximab in the treatment of primary antiphospholipid syndrome: analysis of 24 cases from the bibliography review | Q33414398 | ||
| The "primary" antiphospholipid syndrome: major clinical and serological features. | Q33416915 | ||
| Primary antiphospholipid syndrome: features of patients with raised anticardiolipin antibodies and no other disorder | Q33433089 | ||
| Antiphospholipid antibodies and reproduction: the antiphospholipid antibody syndrome. | Q33547975 | ||
| The antiphospholipid syndrome: immunologic and clinical aspects. Clinical spectrum and treatment | Q33899919 | ||
| Renal involvement in primary antiphospholipid syndrome: retrospective analysis of 160 patients | Q33944778 | ||
| EULAR recommendations for the management of systemic lupus erythematosus with neuropsychiatric manifestations: report of a task force of the EULAR standing committee for clinical affairs | Q34132211 | ||
| 14th International Congress on Antiphospholipid Antibodies: task force report on antiphospholipid syndrome treatment trends | Q34400373 | ||
| Treatment of refractory obstetric antiphospholipid syndrome: the state of the art and new trends in the therapeutic management. | Q34476952 | ||
| Guidelines on the prevention, diagnosis, and treatment of infective endocarditis (new version 2009): the Task Force on the Prevention, Diagnosis, and Treatment of Infective Endocarditis of the European Society of Cardiology (ESC). Endorsed by the Eu | Q34611253 | ||
| Management of antiphospholipid syndrome | Q34989343 | ||
| How I treat the antiphospholipid syndrome | Q34991343 | ||
| Cardiac disease in the antiphospholipid syndrome: recommendations for treatment. Committee consensus report | Q35189299 | ||
| How to treat women with antiphospholipid antibodies in pregnancy? | Q35549772 | ||
| Management of the obstetric antiphospholipid syndrome | Q35743192 | ||
| Prediction of adverse pregnancy outcome by the presence of lupus anticoagulant, but not anticardiolipin antibody, in patients with antiphospholipid antibodies | Q35977256 | ||
| Joint European League Against Rheumatism and European Renal Association-European Dialysis and Transplant Association (EULAR/ERA-EDTA) recommendations for the management of adult and paediatric lupus nephritis | Q36302245 | ||
| Discontinuation of anticoagulation or antiaggregation treatment may be safe in patients with primary antiphospholipid syndrome when antiphospholipid antibodies became persistently negative. | Q51252221 | ||
| Heart valve surgery in patients with the antiphospholipid syndrome: analysis of a series of nine cases. | Q51618414 | ||
| Diagnosis and management of non-criteria obstetric antiphospholipid syndrome. | Q53082840 | ||
| Antiphospholipid syndrome | Q55891386 | ||
| ACOG Practice Bulletin #68: Antiphospholipid syndrome | Q56753299 | ||
| High frequency of antiphospholipid antibodies in relapse of multiple sclerosis: a possible indicator of inflammatory–thrombotic processes | Q59154928 | ||
| IgA anticardiolipin and IgA anti-β2 glycoprotein I antibody positivity determined by fluorescence enzyme immunoassay in primary antiphospholipid syndrome | Q61649470 | ||
| Treatment of 139 Pregnancies in Antiphospholipid-positive Women Not Fulfilling Criteria for Antiphospholipid Syndrome: A Retrospective Study | Q61649488 | ||
| Laboratory and clinical features of pregnant women with antiphospholipid syndrome and neonatal outcome | Q61649548 | ||
| The prevalence and biologic significance of lupus anticoagulant and anticardiolipin antibodies in a general obstetric population | Q61845862 | ||
| High Prevalence of Significant Heart Valve Lesions in Patients with the 'Primary' Antiphospholipid Syndrome | Q67911740 | ||
| Cardiac involvement in patients with primary antiphospholipid syndrome | Q67977013 | ||
| Valvular heart disease in primary antiphospholipid syndrome (PAPS): clinical and morphological findings | Q71115742 | ||
| Prospective Studies of the Association Between Anticardiolipin Antibody and Outcome of Pregnancy | Q72060395 | ||
| Etiology and management of chronic valve disease in antiphospholipid antibody syndrome and systemic lupus erythematosus | Q72292527 | ||
| A systematic review of secondary thromboprophylaxis in patients with antiphospholipid antibodies | Q37020336 | ||
| The antiphospholipid syndrome and heart valve surgery | Q37033025 | ||
| Effect of rituximab on clinical and laboratory features of antiphospholipid syndrome: a case report and a review of literature. | Q37035823 | ||
| The antiphospholipid syndrome as a neurological disease | Q37549406 | ||
| The cardiac manifestations of antiphospholipid syndrome and their echocardiographic recognition | Q37607873 | ||
| Combination of heparin and aspirin is superior to aspirin alone in enhancing live births in patients with recurrent pregnancy loss and positive anti-phospholipid antibodies: a meta-analysis of randomized controlled trials and meta-regression | Q37645693 | ||
| Revisiting the molecular mechanism of neurological manifestations in antiphospholipid syndrome: beyond vascular damage | Q37704593 | ||
| The mosaic of "seronegative" antiphospholipid syndrome | Q37704857 | ||
| Heparin treatment in antiphospholipid syndrome with recurrent pregnancy loss: a systematic review and meta-analysis | Q37760751 | ||
| Acute transverse myelitis and antiphospholipid antibodies in lupus. No evidence for anticoagulation. | Q37788783 | ||
| Pathogenesis of antiphospholipid syndrome: understanding the antibodies | Q37873720 | ||
| Clinical manifestations of antiphospholipid syndrome (APS) with and without antiphospholipid antibodies (the so-called 'seronegative APS'). | Q37939702 | ||
| Does seronegative antiphospholipid syndrome really exist? | Q37950727 | ||
| Correct laboratory approach to APS diagnosis and monitoring. | Q38065593 | ||
| Duration of anticoagulation treatment for thrombosis in APS: is it ever safe to stop? | Q38089684 | ||
| Seronegative antiphospholipid syndrome | Q38090375 | ||
| Movement disorders in systemic lupus erythematosus and the antiphospholipid syndrome | Q38098473 | ||
| 14th International Congress on Antiphospholipid Antibodies Task Force report on obstetric antiphospholipid syndrome | Q38197819 | ||
| 14th International Congress on Antiphospholipid Antibodies Task Force. Report on antiphospholipid syndrome laboratory diagnostics and trends | Q38211487 | ||
| Obstetrical APS: is there a place for hydroxychloroquine to improve the pregnancy outcome? | Q38245425 | ||
| Update on the current recommendations and outcomes in pregnant women with antiphospholipid syndrome | Q38258585 | ||
| Hughes syndrome and multiple sclerosis. | Q38261156 | ||
| Patient-level analysis of five international cohorts further confirms the efficacy of aspirin for the primary prevention of thrombosis in patients with antiphospholipid antibodies. | Q38280730 | ||
| Thin-layer chromatography immunostaining in detecting anti-phospholipid antibodies in seronegative anti-phospholipid syndrome | Q39404443 | ||
| Valvular dysfunction in antiphospholipid syndrome: prevalence, clinical features, and treatment | Q41587455 | ||
| Vimentin/cardiolipin complex as a new antigenic target of the antiphospholipid syndrome | Q42969030 | ||
| Antibodies to domain I of β-2-glycoprotein I and IgA antiphospholipid antibodies in patients with 'seronegative' antiphospholipid syndrome | Q43090289 | ||
| Pregnancy outcome in different clinical phenotypes of antiphospholipid syndrome | Q43246259 | ||
| Successful pregnancy outcome following 19 consecutive miscarriages: case report | Q44673962 | ||
| Transverse myelitis as the first manifestation of systemic lupus erythematosus or lupus-like disease: good functional outcome and relevance of antiphospholipid antibodies | Q44754455 | ||
| What do we know about the cardiac valve lesion in the antiphospholipid syndrome (APS)? | Q44811981 | ||
| The heart in the primary antiphospholipid syndrome. | Q45185947 | ||
| New oral anticoagulants in thrombotic antiphospholipid syndrome. | Q45868646 | ||
| Low-molecular-weight heparin versus intravenous immunoglobulin for recurrent abortion associated with antiphospholipid antibody syndrome | Q46179258 | ||
| Transverse myelitis affecting more than 4 spinal segments associated with systemic lupus erythematosus: clinical, immunological, and radiological characteristics of 22 patients | Q46235776 | ||
| Evolution of cardiac dysfunction in patients with antiphospholipid antibodies and/or antiphospholipid syndrome: a 10-year follow-up study. | Q46300288 | ||
| Antiphospholipid antibody-associated chorea | Q46313657 | ||
| Management of the controversial aspects of the antiphospholipid syndrome pregnancies: a guide for clinicians and researchers | Q46574638 | ||
| Valvular heart disease in the primary antiphospholipid syndrome | Q46730841 | ||
| Anticoagulation treatment withdrawal in primary antiphospholipid syndrome when anticardiolipin antibodies become negative | Q46753205 | ||
| Neuronal-binding antibodies from patients with antiphospholipid syndrome induce cognitive deficits following intrathecal passive transfer | Q48249236 | ||
| P433 | issue | 10 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | antiphospholipid syndrome | Q582207 |
| P304 | page(s) | 586-596 | |
| P577 | publication date | 2015-06-30 | |
| P1433 | published in | Nature Reviews Rheumatology | Q2107227 |
| P1476 | title | Current treatment of antiphospholipid syndrome: lights and shadows | |
| P478 | volume | 11 |
| Q92639094 | Anaesthetic considerations for patients with antiphospholipid syndrome undergoing non-cardiac surgery |
| Q64074958 | Antiphospholipid Antibodies Overlapping in Isolated Neurological Syndrome and Multiple Sclerosis: Neurobiological Insights and Diagnostic Challenges |
| Q59808719 | Antiphospholipid Syndrome and the Neurologist: From Pathogenesis to Therapy |
| Q30235423 | Antiphospholipid syndrome |
| Q58602902 | Antiphospholipid syndrome: state of the art on clinical practice guidelines |
| Q24185949 | Antiplatelet and anticoagulant agents for secondary prevention of stroke and other thromboembolic events in people with antiphospholipid syndrome |
| Q47884958 | Antiplatelet and anticoagulant agents for secondary prevention of stroke and other thromboembolic events in people with antiphospholipid syndrome. |
| Q38991010 | Dangerous liaisons: complement, coagulation, and kallikrein/kinin cross-talk act as a linchpin in the events leading to thromboinflammation |
| Q47998109 | Diagnosing antiphospholipid syndrome: 'extra-criteria' manifestations and technical advances |
| Q47982275 | Diagnosis and management of the antiphospholipid syndrome |
| Q64060824 | High risk of adverse pregnancy outcomes in women with a persistent lupus anticoagulant |
| Q31101744 | Hughes syndrome and epilepsy: when to test for antiphospholipid antibodies? |
| Q41200243 | Increased heterogeneity of brain perfusion is an early marker of central nervous system involvement in antiphospholipid antibody carriers. |
| Q38934375 | Kidney disease in primary anti-phospholipid antibody syndrome |
| Q49171841 | Kidney involvement in antiphospholipid syndrome - current diagnostic and management problems |
| Q93060997 | Managing antiphospholipid syndrome in pregnancy |
| Q33739280 | Plasma levels of high-mobility group box 1 and soluble receptor for advanced glycation end products in primary antiphospholipid antibody syndrome patients. |
| Q89453447 | Seronegative antiphospholipid syndrome: refining the value of "non-criteria" antibodies for diagnosis and clinical management |
| Q42646992 | Subsequent Thrombotic Outcomes in Patients with Ischemic Stroke with Antiphospholipid Antibody Positivity |
| Q38873953 | The antiphospholipid syndrome: from pathophysiology to treatment. |
| Q38635924 | Thyroid Autoimmunity and Antiphospholipid Syndrome: Not Such a Trivial Association |
| Q98290531 | Treatment of Secondary Chorea: A Review of the Current Literature |
| Q47968875 | Undifferentiated connective tissue diseases and adverse pregnancy outcomes. An undervalued association? |
| Q90416101 | [Antiphospholipid syndrome : Update on diagnostics and management] |
Search more.